Loading clinical trials...

Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy | Clinical Trials | Clareo Health

WITHDRAWNPHASE4

Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy

Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy: Prospective Longitudinal Study Over 12 Months.

NCT01841814•Centre Hospitalier Universitaire, Amiens

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess changes of bone mineral density (BMD) at 12 months during the therapeutic management of patients with lymphoma.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects aged 18 to 80 with lymphoma,
•Histological diagnosis of Hodgkin's lymphoma (HL) or non-Hodgkin lymphoma (NHL) of follicular or aggressive (large cell or other),
•Patients who have not yet started their chemotherapy or who have started for less than a month
•Patient has signed informed consent.

Exclusion Criteria

•Pathological fractures at the time of initial diagnosis of lymphoma,
•Compression of neurological epidural,
•Patients receiving treatment for osteoporosis (including bisphosphonates, selective modulators of estrogen receptor, calcitonin and parathyroid hormone Teriparatide).
•Discovery of osteoporosis or osteopenia fracture during the initial evaluation requiring the establishment of an osteoporosis treatment,
•Radiotherapy to the lumbar spine or hip studied,
•Location of bone lymphoma in the lumbar spine or hip studied,
•History of disorders affecting bone metabolism (prostate cancer with androgen, stomach cancer, hyperparathyroidism, hyperthyroidism, uncontrolled ...)
•A person incapable of giving consent personally,
•Pregnant or breastfeeding women,
•Protected Person (under guardianship)
+1 more criteria

Locations (1)

Gandhi DAMAJ

Amiens, Picardie, France

Key Dates

Start Date

April 1, 2013

Primary Completion Date

April 1, 2013

Completion Date

April 1, 2013

Last Updated

December 5, 2016

Conditions

LymphomaOsteoporosis

Interventions

Bone densitometry.

RADIATION

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

NCT06263491

Mantle Cell Lymphoma

View study

RECRUITINGPHASE1

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563

Lymphoma, T Cell, PeripheralT-cell Lymphoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 5, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy

Inclusion Criteria

Exclusion Criteria

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

U69-CART-Cells For R/R T-ALL